Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Omid HamidJessica C HasselAlexander N ShoushtariFriedegund MeierTodd M BauerApril K S SalamaJohn M KirkwoodPaolo Antonio AsciertoPaul C LoriganCornelia MauchMarlana OrloffThomas R Jeffry EvansChris HollandRamakrishna EdukullaShaad E AbedinMark Ross MiddletonPublished in: Journal for immunotherapy of cancer (2023)
NCT02535078.